Shasun Pharma’s performance has been highly erratic. However, the expectation that Shasun will benefit heavily as a result of the Sevelamer molecule drugs going off patent in the US has sent investors into a buying frenzy
Top 15 Stock Picks for Nifty Dec'24 target of 23000. Past recos delivered impressive YoY return of 46% vs Nifty's 27% return. Return since inception is 264% vs Nifty's 137% return. Picks are superior quality stocks with growth potential at reasonable valuations Download research report
Recent Comments